(DVAX) Dynavax Technologies - Ratings and Ratios

Dynavax Technologies Corporation (NASDAQ:DVAX) is a commercial-stage biopharmaceutical company specializing in the development and commercialization of innovative vaccines. Its lead product, HEPLISAV-B, is a next-generation hepatitis B vaccine designed to protect against all known subtypes of the hepatitis B virus in adults aged 18 and older. This vaccine leverages Dynavaxs proprietary CpG 1018 adjuvant, which enhances immune response. The company also has a pipeline that includes rF1V, a plague vaccine candidate in Phase 2 clinical trials, and Z-1018, an investigational shingles vaccine in Phase 1/2 clinical trials for adults aged 50 and older. Dynavax distributes its products through a network of wholesalers, specialty distributors, and directly to hospitals, clinics, public health institutions, and government agencies, including the Department of Defense and Department of Veterans Affairs. The company collaborates with global partners such as the U.S. Department of Defense, the Coalition for Epidemic Preparedness Innovations, and Biological E. Limited. Originally founded as Double Helix Corporation in 1996, Dynavax Technologies Corporation is headquartered in Emeryville, California.

Based on the provided and , here is a 3-month forecast for Dynavax Technologies Corporation:

Stock Price Forecast: - The stock is currently trading at $11.33 with a 20-day SMA of $11.30 and a 50-day SMA of $12.71. - The 200-day SMA is $12.09, indicating a potential bullish trend if the price crosses above $12.09. - ATR of 0.49 suggests moderate volatility over the next 3 months. - If the stock breaks above $12.50, it could test $14.00. If it breaks below $10.50, it could test $9.00.

Valuation and Performance Forecast: - Market cap of $1.28B reflects moderate growth potential. - The forward P/E of 29.50 indicates investor confidence in future earnings. - The P/S ratio of 4.61 suggests the stock is fairly valued relative to its revenue. - With an RoE of 4.58, the company is expected to maintain its profitability in the near term. - The stock may experience increased interest if the company announces positive clinical trial results or new collaborations.